Comparison 4. Methotrexate and Infliximab versus Infliximab.
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Failure to enter remission at 14 weeks or 24 weeks | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
2 Adverse events | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
3 Serious adverse events | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
4 Withdrawals due to adverse event | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected |